Abstract:Imipramine hydrochloride (IMP), a tricyclic antidepressant used for major depression, enuresis, and neuropathic pain, is limited by gastrointestinal complications, low oral bioavailability (44%), and complex dosing requirements. This study aimed to explore a novel non-invasive nasal delivery system using chitosan nanoparticles (Cs NPs) embedded in an in situ gel to address the limitations of oral IMP administration. Cs NPs loaded with IMP were synthesized via ionic gelation and assessed for precision in drug concentration using a validated HPLC method. The particles were integrated into a thermoresponsive polymer, Pluronic F127, to form an in situ gel suitable for nasal administration. The formulation was characterized for gelation temperature, duration, viscosity, mucoadhesive strength, and overall gel robustness. Drug release kinetics and the controlled release mechanism were studied using ex vivo permeation tests with Franz diffusion cells and nasal sheep mucosa. The optimized nanoparticle formulation (F4-50) exhibited a consistent PS of 141.7 ± 2.2 nm, a zeta potential (ZP) of 16.79 ± 2.1 mV, and a high encapsulation efficiency of 67.71 ± 1.9%. The selected in situ gel formulation, F4-50-P1, demonstrated a gelation temperature of 33.6 ± 0.94 °C and a rapid gelation time of 48.1 ± 0.7 s. Transform-attenuated total reflectance infrared spectroscopy (ATR-IR) confirmed the compatibility and effective encapsulation of IMP within the formulation. The release profile of F4-50 included an initial burst release followed by a sustained release phase, with F4-50-P1 showing improved control over the burst release. The flux rates were 0.50 ± 0.01 mg/cm2/h for F4-50 and 0.33 ± 0.06 mg/cm2/h for F4-50-P1, indicating effective permeation. The developed chitosan nanoparticle-based in situ gel formulation provides a promising approach for the controlled release of IMP, enhancing therapeutic efficacy and patient compliance while mitigating the disadvantages associated with oral delivery.

Preparation of Ion-Activated in Situ Gel Systems of Scopolamine Hydrobromide and Evaluation of Its Antimotion Sickness Efficacy

Effects of Nasal Gingerol Gel on Motion Sickness

Preparation of Ion-Activated in Situ Gel Systems for Nasal Use and Its Elimination Pharmacokinetic Study in Rabbits

Effect of ginger transderm scopolamine on changes of enzymes activity in brain tissue of rat suffered from motion sickness

Motion Sickness Treatment Analysis with OVAR

Formulation and Evaluation of In Situ Gelling Systems for Intranasal Administration of Gastrodin

In situ gel based on gellan gum as new carrier for nasal administration of mometasone furoate.

An in situ gel system for nasal delivery of menthol: preparation and safety evaluation

Microdialysis Pharmacokinetic Study of Scopolamine in Plasma, Olfactory Bulb and Vestibule after Intranasal Administration

Metoclopramide nasal spray in vitro evaluation and in vivo pharmacokinetic studies in dogs

Anti-cholinergics Mecamylamine and Scopolamine Alleviate Motion Sickness-Induced Gastrointestinal Symptoms Through Both Peripheral and Central Actions

Formulation of Metoclopramide Hydrochloride-Loaded Lipid Carriers by QbD Approach for Combating Nausea: Safety and Bioavailability Evaluation in New Zealand Rabbit

The Combination of Scopolamine and Psychostimulants for the Prevention of Severe Motion Sickness.

A Combination of Gamma-Aminobutyric Acid, Glutamic Acid, Calcium, Thiamine, Pyridoxine, and Cyanocobalamin vs Ginger Extract in the Management of Chronic Motion Sickness: A Clinical Evaluation

Experimental Study on Treatment of Motion Sickness by Quick-Acting Anti-Motion Capsule

Optimization of Extraction Technology of Jiangxia Formulation Against Motion Sickness

Orexin-A Attenuated Motion Sickness Through Modulating Neural Activity in Hypothalamus Nuclei

Chitosan Nanoparticles Embedded in In Situ Gel for Nasal Delivery of Imipramine Hydrochloride: Short-Term Stage Development and Controlled Release Evaluation

Brown Slime Cap Mushroom (Chroogomphus rutilus, Agaricomycetes) Polysaccharide Resists Motion Sickness by Inhibiting the Activity of the Serotonin System in Mice

Formulation development and evaluation of nasal in situ gel of promethazine hydrochloride

Formulation and evaluation of niosomal vesicles containing ondansetron HCL for trans-mucosal nasal drug delivery